| Customization: | Available |
|---|---|
| CAS No.: | 5266-20-6 |
| Formula: | C5h5lin2o4 |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Mechanism of Action: Lithium modulates neurotransmitter activity (e.g., serotonin, dopamine, glutamate) and enhances neuroprotective factors (e.g., BDNF). Unlike lithium carbonate, lithium orotate is believed to have better cellular uptake due to orotate's role in mineral transport.
Bioavailability: May require lower doses than lithium carbonate due to improved permeability.
Mood stabilization: Anecdotal reports for mild mood swings, anxiety, and irritability.
Neuroprotection: Proposed benefits in neurodegenerative conditions (e.g., Alzheimer's, TBI).
Alcohol use disorder: Some studies suggest reduced relapse risk.
Off-label/Experimental: Bipolar disorder (though not FDA-approved for this use).
Typical supplement dose: 5-20 mg lithium (elemental) per day (often as 1-2 tablets of lithium orotate).
Higher doses (>30 mg/day): Should be medically supervised (risk of toxicity).
Unlike prescription lithium (carbonate/citrate): Not standardized for psychiatric use.
Common (at low doses): Mild GI upset, thirst, or fatigue.
Serious (high doses or chronic use):
Lithium toxicity (tremors, confusion, renal impairment).
Thyroid/kidney dysfunction (long-term risk, as with other lithium forms).
Electrolyte imbalances (e.g., hyponatremia).
Kidney disease (impaired lithium excretion).
Cardiovascular instability (e.g., severe arrhythmias).
Pregnancy/nursing (risk of fetal harm).
Concurrent diuretic use (increases lithium retention).
){kind=link}